Johnson & Johnson reported fourth-quarter revenue of 24.56 billion, representing 9.1 percent year-over-year growth and surpassing consensus projections of 24.15 billion. Adjusted earnings per share reached 2.46, well ahead of the 2.04 estimate, driven by robust demand for medical technology products and a 27 percent surge in sales of Darzalex, the company’s leading blood cancer therapy. Results were partially offset by declining volumes of Stelara in the face of intensified biosimilar competition, but operational sales growth of 7.1 percent demonstrated broad resilience across its Innovative Medicine and MedTech segments.

The company issued full-year guidance projecting sales between 100 billion and 101 billion, topping the consensus forecast of 98.9 billion, and adjusted earnings per share of 11.43 to 11.63, above the 11.45 street estimate. This outlook factors in a “hundreds of millions” dollar headwind from a recently concluded drug pricing agreement with the U.S. government, underscoring Johnson & Johnson’s confidence in operational execution and cost management. CFO Joseph Wolk noted that the agreement aligns with broader industry moves while preserving tariff exemptions, and that the forecast still exceeds Wall Street expectations despite this concession.

Oncology remained the company’s fastest-growing franchise, with combined sales of Darzalex, Carvykti and Erleada contributing to year-over-year growth of nearly 25 percent in the cancer portfolio. Immunology products such as Tremfya and Simponi delivered mid-single-digit increases, offsetting a double-digit decline in Stelara. In MedTech, sales grew 7.5 percent to 8.80 billion, propelled by electrophysiology devices, Abiomed circulatory support systems and advanced wound closure products. The company highlighted that both Carvykti and the Shockwave atherectomy platform have now crossed the 1 billion revenue threshold, reflecting successful commercial launches and expanding patient access.